Aritinercept

Preclinical

Aurinia Pharmaceuticals

Aritinercept is one of 4 therapeutic programs targeting Myasthenia Gravis, Generalized. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Myasthenia Gravis, GeneralizedRecruiting

Myasthenia Gravis, GeneralizedPreclinical

Recruiting

Competition

Competitive Landscape

3 competitors in Myasthenia Gravis, Generalized

#DrugCompanyPhaseTrials

Vyvgart

Argenx

Approved

1 2

Claseprubart

DDianthus Therapeutics

Phase 3

2 3

Descartes-08

CCartesian Therapeutics

Phase 2

1 4

Aritinercept

Aurinia Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

PreclinicalRecruiting

Myasthenia Gravis, Generalized

NCT07596901

Clinical

Trials by Indication[1]

Myasthenia Gravis, Generalized1 trial

A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients With Generalized Myasthenia Gravis

Recruiting· Aurinia Pharmaceuticals logo

Aurinia Pharmaceuticals·Preclinical·NCT07596901·81 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Aritinercept. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Aritinercept. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Aurinia Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: Aurinia Pharmaceuticals

Aritinercept

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Myasthenia Gravis, Generalized1 trial

References

Drug Info

Quick Facts

Related News